The exponential spending growth in oncology has resulted in myriad utilization management strategies by both payers and providers to control costs, especially drug costs. Precision's Julianna Kula, Bruce Edelen, Ronald Schleif, Jeffrey Becker, Mark Urban, and Elizabeth Oyekan explore current and emerging drug utilization management strategies being employed to help curtail oncology costs without adversely impacting patient quality and outcomes.

LEARN MORE

More pushback against copay programs likely on the horizon: Precision's Ryan Cox and Reta Mourad, PharmD, FNTP discuss why a federal court's decision striking down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs, as well as a recent pharma lawsuit against a maximizer company, could spur more states to take action of their own.

LEARN MORE

Orphan drugs for rare diseases are now frequently found in big pharma pipelines. Payers have had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline. Precision's Phil Cyr and Erin Lopata weigh in on new ways to pay for them.

LEARN MORE

A federal court recently struck down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs. Precision's Ryan Cox and Reta Mourad weigh in on why the decision may spur more pushback against these copay programs.

LEARN MORE

The COVID-19 pandemic served as a catalyst for the expansion and uptake of telehealth and virtual care for office visits and outpatient care, which rose from less than 1% utilization in 2019 to more than 50% at the height of the pandemic in 2020. Now, as the pandemic stabilizes, virtual care visits have declined significantly and have largely stabilized at about 10% of health care visits. Precision's Elizabeth Oyekan and Reta Mourad discuss three reasons that virtual care and telehealth care are here to stay.

LEARN MORE

Dive into the evolving PBM landscape as PRECISIONvalue's Sejal Jonas explores tactics to bring new DUM tools to the market to effectively manage drug costs and spend.

LEARN MORE

PRECISIONvalue's Ryan Cox examines the increasing level of influence IDNs have over drug therapy prescribing and what tools they are leveraging to manage drug costs and spend.

LEARN MORE

PRECISIONvalue's Barbara Henry points out that while DUMs are a vital cost-savings tool, the administrative burden can be extremely high. In this overview, she offers some new strategies to minimize the administrative impact while still controlling cost.

LEARN MORE

PRECISIONvalue's Dorothy Agyemang and Elizabeth Oyekan do a deep dive into some of CMS’s current and proposed actions, focusing on both offense and defense tactics to address the rising costs of drugs.

LEARN MORE